Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 668, Issue 1-2, 2009, Pages 141-149

  Müller, Lars U W ^a,b,c   Williams, David A ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Bone marrow failure; Fanconi anemia; Gene therapy; HSC

Indexed keywords

CYCLOPHOSPHAMIDE; DIPROTIN A; ETANERCEPT; FANCONI ANEMIA GROUP C PROTEIN; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OXANDROLONE; OXYMETHOLONE; PLERIXAFOR; PROSTAGLANDIN E2 DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; BONE MARROW DEPRESSION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FANCONI ANEMIA; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC GENE THERAPY; STEM CELL MOBILIZATION; THERAPY EFFECT; THROMBOCYTE TRANSFUSION;

ANIMALS; BONE MARROW DISEASES; CYTOKINES; FANCONI ANEMIA; FORECASTING; GENE THERAPY; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; TISSUE THERAPY;

EID: 67650429712     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.03.010     Document Type: Review

References (106)

1. Alter B.P., and Rosenberg P.S. Granulocyte colony-stimulating factor and severe aplastic anemia. Blood 109 (2007) 4589 (author reply 4589-4590)
2. Kutler D.I., Singh B., Satagopan J., Batish S.D., Berwick M., Giampietro P.F., Hanenberg H., and Auerbach A.D. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101 (2003) 1249-1256
3. Butturini A., Gale R.P., Verlander P.C., Adler-Brecher B., Gillio A.P., and Auerbach A.D. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry Study. Blood 84 (1994) 1650-1655
4. Scheinberg P., Wu C.O., Nunez O., and Young N.S. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J. Pediatr. 153 (2008) 814-819
5. Smogorzewska A., Matsuoka S., Vinciguerra P., McDonald III E.R., Hurov K.E., Luo J., Ballif B.A., Gygi S.P., Hofmann K., D'Andrea A.D., and Elledge S.J. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 129 (2007) 289-301
6. Andreassen P.R., D'Andrea A.D., and Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18 (2004) 1958-1963
7. Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., Kim S.T., Lane W.S., Kastan M.B., and D'Andrea A.D. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109 (2002) 459-472
8. Taniguchi T., and D'Andrea A.D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107 (2006) 4223-4233
9. D'Andrea A.D., and Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer. 3 (2003) 23-34
10. Kalb R., Neveling K., Hoehn H., Schneider H., Linka Y., Batish S.D., Hunt C., Berwick M., Callen E., Surralles J., Casado J.A., Bueren J., Dasi A., Soulier J., Gluckman E., Zwaan C.M., van Spaendonk R., Pals G., de Winter J.P., Joenje H., Grompe M., Auerbach A.D., Hanenberg H., and Schindler D. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am. J. Hum. Genet. 80 (2007) 895-910
11. Dufour C., Rondelli R., Locatelli F., Miano M., Di Girolamo G., Bacigalupo A., Messina C., Porta F., Balduzzi A., Iorio A.P., Buket E., Madon E., Pession A., Dini G., and Di Bartolomeo P. Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of AIEOP-GITMO. Br. J. Haematol. 112 (2001) 796-805
12. Nistico A., and Young N.S. Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia. Ann. Intern. Med. 120 (1994) 463-469
13. Schultz J.C., and Shahidi N.T. Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am. J. Hematol. 42 (1993) 196-201
14. Rosselli F., Sanceau J., Gluckman E., Wietzerbin J., and Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood 83 (1994) 1216-1225
15. Dufour C., Corcione A., Svahn J., Haupt R., Poggi V., Beka'ssy A.N., Scime R., Pistorio A., and Pistoia V. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102 (2003) 2053-2059
16. Rathbun R.K., Faulkner G.R., Ostroski M.H., Christianson T.A., Hughes G., Jones G., Cahn R., Maziarz R., Royle G., Keeble W., Heinrich M.C., Grompe M., Tower P.A., and Bagby G.C. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 90 (1997) 974-985
17. Whitney M.A., Royle G., Low M.J., Kelly M.A., Axthelm M.K., Reifsteck C., Olson S., Braun R.E., Heinrich M.C., Rathbun R.K., Bagby G.C., and Grompe M. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 88 (1996) 49-58
18. Haneline L.S., Broxmeyer H.E., Cooper S., Hangoc G., Carreau M., Buchwald M., and Clapp D.W. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 91 (1998) 4092-4098
19. Li X., Yang Y., Yuan J., Hong P., Freie B., Orazi A., Haneline L.S., and Clapp D.W. Continuous in vivo infusion of interferon-gamma (IFN-gamma) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice. Blood 104 (2004) 1204-1209
20. Li J., Sejas D.P., Zhang X., Qiu Y., Nattamai K.J., Rani R., Rathbun K.R., Geiger H., Williams D.A., Bagby G.C., and Pang Q. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J. Clin. Invest. 117 (2007) 3283-3295
21. Fanconi Anemia: Standards for Clinical Care, Fanconi Anemia Research Fund Inc., Eugene, OR, 2003.
22. Wagner J.E., Eapen M., MacMillan M.L., Harris R.E., Pasquini R., Boulad F., Zhang M.J., and Auerbach A.D. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 109 (2007) 2256-2262
23. Shahidi N.T., and Diamond L.K. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N. Engl. J. Med. 264 (1961) 953-967
24. Diamond L.K., and Shahidi N.T. Treatment of aplastic anemia in children. Semin. Hematol. 4 (1967) 278-288
25. Guinan E.C., Lopez K.D., Huhn R.D., Felser J.M., and Nathan D.G. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with Fanconi anemia. J. Pediatr. 124 (1994) 144-150
26. Rackoff W.R., Orazi A., Robinson C.A., Cooper R.J., Alter B.P., Freedman M.H., Harris R.E., and Williams D.A. Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 88 (1996) 1588-1593
27. Gluckman E., Devergie A., and Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br. J. Haematol. 54 (1983) 431-440
28. Berger R., Bernheim A., Gluckman E., and Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br. J. Haematol. 45 (1980) 565-568
29. Gluckman E., Auerbach A.D., Horowitz M.M., Sobocinski K.A., Ash R.C., Bortin M.M., Butturini A., Camitta B.M., Champlin R.E., Friedrich W., et al. Bone marrow transplantation for Fanconi anemia. Blood 86 (1995) 2856-2862
30. Farzin A., Davies S.M., Smith F.O., Filipovich A., Hansen M., Auerbach A.D., and Harris R.E. Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience. Br. J. Haematol. 136 (2007) 633-640
31. Guardiola P., Pasquini R., Dokal I., Ortega J.J., van Weel-Sipman M., Marsh J.C., Ball S.E., Locatelli F., Vermylen C., Skinner R., Ljungman P., Miniero R., Shaw P.J., Souillet G., Michallet M., Bekassy A.N., Krivan G., Di Bartolomeo P., Heilmann C., Zanesco L., Cahn J.Y., Arcese W., Bacigalupo A., and Gluckman E. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 95 (2000) 422-429
32. Chaudhury S., Auerbach A.D., Kernan N.A., Small T.N., Prockop S.E., Scaradavou A., Heller G., Wolden S., O'Reilly R.J., and Boulad F. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br. J. Haematol. 140 (2008) 644-655
33. Muller L.U., Milsom M.D., Kim M.O., Schambach A., Schuesler T., and Williams D.A. Rapid lentiviral transduction preserves the engraftment potential of Fanca(-/-) hematopoietic stem cells. Mol. Ther. 16 (2008) 1154-1160
34. Liu J.M., Kim S., Read E.J., Futaki M., Dokal I., Carter C.S., Leitman S.F., Pensiero M., Young N.S., and Walsh C.E. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum. Gene Ther. 10 (1999) 2337-2346
35. Kelly P.F., Radtke S., Kalle C., Balcik B., Bohn K., Mueller R., Schuesler T., Haren M., Reeves L., Cancelas J.A., Leemhuis T., Harris R., Auerbach A.D., Smith F.O., Davies S.M., and Williams D.A. Stem cell collection and gene transfer in fanconi anemia. Mol. Ther. 15 (2007) 211-219
36. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., Glimm H., Kuhlcke K., Schilz A., Kunkel H., Naundorf S., Brinkmann A., Deichmann A., Fischer M., Ball C., Pilz I., Dunbar C., Du Y., Jenkins N.A., Copeland N.G., Luthi U., Hassan M., Thrasher A.J., Hoelzer D., von Kalle C., Seger R., and Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12 (2006) 401-409
37. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., and Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
38. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672 (see comments)
39. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., Brouns G., Schmidt M., Von Kalle C., Barington T., Jakobsen M.A., Christensen H.O., Al Ghonaium A., White H.N., Smith J.L., Levinsky R.J., Ali R.R., Kinnon C., and Thrasher A.J. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
40. Kohn D.B., Hershfield M.S., Carbonaro D., Shigeoka A., Brooks J., Smogorzewska E.M., Barsky L.W., Chan R., Burotto F., Annett G., Nolta J.A., Crooks G., Kapoor N., Elder M., Wara D., Bowen T., Madsen E., Snyder F.F., Bastian J., Muul L., Blaese R.M., Weinberg K., and Parkman R. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4 (1998) 775-780
41. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
42. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., Macintyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., and Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118 (2008) 3132-3142
43. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., Gilmour K.C., Adams S., Thornhill S.I., Parsley K.L., Staal F.J., Gale R.E., Linch D.C., Bayford J., Brown L., Quaye M., Kinnon C., Ancliff P., Webb D.K., Schmidt M., von Kalle C., Gaspar H.B., and Thrasher A.J. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118 (2008) 3143-3150
44. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kuhlcke K., Eckert H.G., Fehse B., and Baum C. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
45. Modlich U., Bohne J., Schmidt M., von Kalle C., Knob S., Schambach A., and Baum C. Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108 (2006) 2545-2553
46. Kustikova O., Fehse B., Modlich U., Yang M., Dullmann J., Kamino K., von Neuhoff N., Schlegelberger B., Li Z., and Baum C. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308 (2005) 1171-1174
47. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
48. Cattoglio C., Facchini G., Sartori D., Antonelli A., Miccio A., Cassani B., Schmidt M., von Kalle C., Howe S., Thrasher A.J., Aiuti A., Ferrari G., Recchia A., and Mavilio F. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110 (2007) 1770-1778
49. Cavazzana-Calvo M., and Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet?. J. Clin. Invest. 117 (2007) 1456-1465
50. Zychlinski D., Schambach A., Modlich U., Maetzig T., Meyer J., Grassman E., Mishra A., and Baum C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16 (2008) 718-725
51. Emery D.W., Yannaki E., Tubb J., and Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9150-9155
52. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267 (see comments)
53. Mostoslavsky G., Kotton D.N., Fabian A.J., Gray J.T., Lee J.S., and Mulligan R.C. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol. Ther. 11 (2005) 932-940
54. Kurre P., Anandakumar P., and Kiem H.P. Rapid 1-hour transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells. Gene Ther. 13 (2006) 369-373
55. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., Sergi L.S., Benedicenti F., Ambrosi A., Di Serio C., Doglioni C., von Kalle C., and Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24 (2006) 687-696
56. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., Oostra A.B., Veerman A.J., van Weel M., Pauli R.M., Shahidi N.T., Dokal I., Roberts I., Altay C., Gluckman E., Gibson R.A., Mathew C.G., Arwert F., and Joenje H. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur. J. Hum. Genet. 5 (1997) 137-148
57. Gross M., Hanenberg H., Lobitz S., Friedl R., Herterich S., Dietrich R., Gruhn B., Schindler D., and Hoehn H. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet. Genome Res. 98 (2002) 126-135
58. Mankad A., Taniguchi T., Cox B., Akkari Y., Rathbun R.K., Lucas L., Bagby G., Olson S., D'Andrea A., and Grompe M. Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 107 (2006) 3084-3090
59. Waisfisz Q., Morgan N.V., Savino M., de Winter J.P., van Berkel C.G., Hoatlin M.E., Ianzano L., Gibson R.A., Arwert F., Savoia A., Mathew C.G., Pronk J.C., and Joenje H. Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nat. Genet. 22 (1999) 379-383
60. Liu G., Excoffon K.J., Benoit P., Ginzinger D.G., Miao L., Ehrenborg E., Duverger N., Denefle P.P., Hayden M.R., and Lewis M.E. Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Hum. Gene Ther. 8 (1997) 205-214
61. Yamada K., Ramezani A., Hawley R.G., Ebell W., Arwert F., Arnold L.W., and Walsh C.E. Phenotype correction of Fanconi anemia group A hematopoietic stem cells using lentiviral vector. Mol. Ther. 8 (2003) 600-610
62. Galimi F., Noll M., Kanazawa Y., Lax T., Chen C., Grompe M., and Verma I.M. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood 100 (2002) 2732-2736
63. Cheng N.C., van de Vrugt H.J., van der Valk M.A., Oostra A.B., Krimpenfort P., de Vries Y., Joenje H., Berns A., and Arwert F. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum. Mol. Genet. 9 (2000) 1805-1811
64. Li X., Le Beau M.M., Ciccone S., Yang F.C., Freie B., Chen S., Yuan J., Hong P., Orazi A., Haneline L.S., and Clapp D.W. Ex vivo culture of Fancc-/- stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood 105 (2005) 3465-3471
65. Battaile K.P., Bateman R.L., Mortimer D., Mulcahy J., Rathbun R.K., Bagby G., Fleming W.H., and Grompe M. In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Blood 94 (1999) 2151-2158
66. Haneline L.S., Gobbett T.A., Ramani R., Carreau M., Buchwald M., Yoder M.C., and Clapp D.W. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood 94 (1999) 1-8
67. Collins Jr. R.H. CD34+ selected cells in clinical transplantation. Stem Cells 12 (1994) 577-585
68. Henon P.R. Peripheral blood stem cell transplantations: past, present and future. Stem Cells 11 (1993) 154-172
69. Croop J.M., Cooper R., Fernandez C., Graves V., Kreissman S., Hanenberg H., Smith F.O., and Williams D.A. Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia. Blood 98 (2001) 2917-2921
70. Auerbach A.D., Liu Q., Ghosh R., Pollack M.S., Douglas G.W., and Broxmeyer H.E. Prenatal identification of potential donors for umbilical cord blood transplantation for Fanconi anemia. Transfusion 30 (1990) 682-687
71. Martinez C., Urbano-Ispizua A., Marin P., Merino A., Rovira M., Carreras E., and Montserrat E. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant. 24 (1999) 1273-1278
72. Kroger N., Rauhoft C., Zeller W., Renges H., Hassan H.T., Kruger W., Schuch G., Wacker-Backhaus G., Colberg H., Kuse R., Gutensohn K., Loliger C., and Zander A.R. Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failure. Acta Haematol. 102 (2000) 144-147
73. Kroger N., Zeller W., Fehse N., Hassan H.T., Kruger W., Gutensohn K., Lolliger C., and Zander A.R. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br. J. Haematol. 102 (1998) 1101-1106
74. -1 CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma. Br. J. Haematol. 118 (2002) 90-100
75. Perez-Duenas B., Alcorta I., Estella J., Rives S., Toll T., and Tuset E. Safety and efficacy of high-dose G-CSF (24 microg/kg) alone for PBSC moblization in children. Bone Marrow Transplant. 30 (2002) 987-988
76. Gazitt Y., Freytes C.O., Callander N., Tsai T.W., Alsina M., Anderson J., Holle L., Cruz J., Devore P., McGrath M., West G., Alvarez R., and Montgomery W. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J. Hematother. 8 (1999) 173-183
77. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., and Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151 (1993) 1548-1561
78. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., and Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 (1997) 141-147
79. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J., and Finck B.K. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342 (2000) 763-769
80. Kohn D.B. Gene therapy for childhood immunological diseases. Bone Marrow Transplant. 41 (2008) 199-205
81. Steensma D.P., Pardanani A., Stevenson W.S., Hoyt R., Kiu H., Grigg A.P., Szer J., Juneja S., Hilton D.J., Alexander W.S., and Roberts A.W. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Blood 107 (2006) 1733-1735 (author reply 1735)
82. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., Liles W.C., Li X., Graham-Evans B., Campbell T.B., Calandra G., Bridger G., Dale D.C., and Srour E.F. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201 (2005) 1307-1318
83. Aiuti A., Webb I.J., Bleul C., Springer T., and Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185 (1997) 111-120
84. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., Nagler A., Ben-Hur H., Many A., Shultz L., Lider O., Alon R., Zipori D., and Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283 (1999) 845-848
85. Broxmeyer H.E., Kohli L., Kim C.H., Lee Y., Mantel C., Cooper S., Hangoc G., Shaheen M., Li X., and Clapp D.W. Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J. Leukoc. Biol. 73 (2003) 630-638
86. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., Calandra G., and DiPersio J.F. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22 (2004) 1095-1102
87. Calandra G., McCarty J., McGuirk J., Tricot G., Crocker S.A., Badel K., Grove B., Dye A., and Bridger G. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 41 (2008) 331-338
88. Pulliam A.C., Hobson M.J., Ciccone S.L., Li Y., Chen S., Srour E.F., Yang F.C., Broxmeyer H.E., and Clapp D.W. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp. Hematol. (2008)
89. Christopherson II K.W., Cooper S., and Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101 (2003) 4680-4686
90. Christopherson II K.W., Hangoc G., and Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 169 (2002) 7000-7008
91. Campbell T.B., Hangoc G., Liu Y., Pollok K., and Broxmeyer H.E. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 16 (2007) 347-354
92. Christopherson II K.W., Hangoc G., Mantel C.R., and Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305 (2004) 1000-1003
93. Tian C., Bagley J., Forman D., and Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther. 13 (2006) 652-658
94. North T.E., Goessling W., Walkley C.R., Lengerke C., Kopani K.R., Lord A.M., Weber G.J., Bowman T.V., Jang I.H., Grosser T., Fitzgerald G.A., Daley G.Q., Orkin S.H., and Zon L.I. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447 (2007) 1007-1011
95. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10 (1990) 4239-4242
96. Reiser J., Harmison G., Kluepfel-Stahl S., Brady R.O., Karlsson S., and Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 15266-15271
97. Si Y., Pulliam A.C., Linka Y., Ciccone S., Leurs C., Yuan J., Eckermann O., Fruehauf S., Mooney S., Hanenberg H., and Clapp D.W. Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. Blood 112 (2008) 4458-4465
98. Kyba M., Perlingeiro R.C., and Daley G.Q. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 109 (2002) 29-37
99. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
100. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
101. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., and Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
102. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., and Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451 (2008) 141-146
103. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., and Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 134 (2008) 877-886
104. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., Beard C., Brambrink T., Wu L.C., Townes T.M., and Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318 (2007) 1920-1923
105. Pasquini R., Carreras J., Pasquini M.C., Camitta B.M., Fasth A.L., Hale G.A., Harris R.E., Marsh J.C., Robinson A.J., Zhang M.J., Eapen M., and Wagner J.E. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol. Blood Marrow Transplant. 14 (2008) 1141-1147
106. Macmillan M.L., Weisdorf D.J., Brunstein C.G., Cao Q., Defor T.E., Verneris M.R., Blazar B.R., and Wagner J.E. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 113 (2009) 2410-2415